[ad_1]
Sun Pharmaceutical Industries share price gained nearly 1 percent in early trade on June 20 after its subsidiary received the Health Canada nod to its acne control solution.
Sun Pharma Canada Inc, a wholly owned subsidiary of Sun Pharmaceutical Industries, announced Health Canada’s approval of WINLEVI (clascoterone cream 1 percent).
WINLEVI is the first and only androgen receptor inhibitor indicated for the topical treatment of acne vulgaris (acne) in patients 12 years of age and older. The newest Health Canada-approved formulation targets the hormonal component of acne for Canadian patients in 40 years of age.
“Sun Pharma is committed to providing innovative dermatology medicines for Canadians, which fill the gap for necessary treatment options,” said Abhay Gandhi, North America CEO of Sun Pharma. “We are thrilled to provide a new topical treatment option for the millions of Canadians affected by acne.”
WINLEVI will be available in Canada this Fall, the company said.
Catch all the market action on our live blog
At 9:26am, Sun Pharmaceutical Industries was quoting at Rs 998, down Rs 3.25, or 0.32 percent on the BSE.
The share touched a 52-week high of Rs 1,071.90 and a 52-week low of Rs 794.25 on 30 January, 2023 and 20 June, 2022, respectively. It is trading 6.89 percent below its 52-week high and 25.65 percent above its 52-week low.
Disclaimer: The views and investment tips expressed by experts on Moneycontrol.com are their own and not those of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
[ad_2]
Source link